We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session Item

Saturday
May 13
10:30 - 11:30
Business Suite 1-2
Lung 1
Jose Belderbos, The Netherlands
Poster Discussion
Clinical
Cardiac dose and survival in stereotactic lung radiotherapy: results of multi-centre SSBROC trial
Vicky Chin, Australia
PD-0158

Abstract

Cardiac dose and survival in stereotactic lung radiotherapy: results of multi-centre SSBROC trial
Authors:

Vicky Chin1,2,3, Phillip Chlap1,2,4, Robert Finnegan5,6,4, Eric Hau7,8,9,10, Anselm Ong7, Xiaobing Ma11, Lois Holloway1,6,2,4, Geoff Delaney1,2,3, Shalini Vinod1,2,3

1University of New South Wales, South Western Sydney Clinical School, Sydney, Australia; 2Liverpool and Macarthur Cancer Therapy Centres, Department of Radiation Oncology, Sydney, Australia; 3Ingham Institute for Applied Medical Research, Radiation Oncology, Sydney, Australia; 4Ingham Institute for Applied Medical Research, Medical Physics, Sydney, Australia; 5Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, Australia; 6University of Sydney, Institute of Medical Physics, Sydney, Australia; 7Crown Princess Mary Cancer Centre, Westmead Hospital, Department of Radiation Oncology, Sydney, Australia; 8Blacktown Haematology and Cancer Centre, Blacktown Hospital, Department of Radiation Oncology, Sydney, Australia; 9Westmead Institute of Medical Research, Centre for Cancer Research, Sydney, Australia; 10University of Sydney, Westmead Clinical School, Sydney, Australia; 11St George Hospital, Division of Cancer services, Sydney, Australia

Show Affiliations
Purpose or Objective

Cardiac toxicity is a potential side effect of thoracic radiotherapy. The majority of studies have been in breast or conventionally fractionated lung radiotherapy patients. While stereotactic ablative body radiotherapy (SABR) is increasingly used in recent years for early stage lung cancer, the impact of dose to the heart, particularly cardiac substructures, in this cohort of patients remains largely unknown. The study looks at doses received by cardiac substructures in SABR patients and impact on survival.

Material and Methods

SSBROC 002 is an Australian multi-centre phase II prospective study of SABR for stage I non-small cell lung cancer (ACTRN12614000478617). Patient were treated between 2013-2019 across 9 centres. A previously developed open-source cardiac substructure automatic segmentation tool for delineating 18 cardiac structures (whole heart, 4 chambers, 3 great vessel bases, 4 coronary arteries, 4 cardiac valves and 2 conduction system nodes) was deployed on the planning CTs of patients in this trial. Raw doses to the cardiac structures including mean dose (Dmean), D0-100%, and EQD2 converted doses (voxel-by-voxel conversion using α/β=3) were calculated. Kaplan-Meier analysis of cardiac doses and survival was performed.

Results

118 SABR patients had cardiac substructure doses and survival analysed. 33 patients received 45-50Gy in 5 fractions, 84 received 48Gy in 4 fractions and 1 had 54Gy in 3 fractions. The Dmean of cardiac structures are illustrated in Figure 1. The median of Dmean across all cardiac structures were 0.21 – 0.65Gy for 5 fractions, 0.12 – 0.52Gy for 4 fractions, and 0.07 – 0.20Gy for 3 fractions. However in cases where tumours were close to the heart, Dmean was as high as 22.5Gy to base of superior vena cava and 18.3Gy to sinoatrial node. When converted to EQD2 doses, Dmean reached 34.4Gy and 25.5Gy for these two structures respectively. Similarly for maximum dose (D0), the median D0 across all cardiac structures ranged from 0.3 – 6.3Gy for 5 fractions, 0.2 – 1.6Gy for 4 fractions, 0.1 – 0.3Gy for 3 fractions. However in selected cases D0 was as high as 51.7Gy to the heart and 45.3Gy to the right atrium. This converted to EQD2 of 137.8Gy and 109.5Gy to these two structures.

Median follow-up was 35.4 months. For cardiac specific toxicity, 4 patients developed pericardial effusion - 3 cases were grade 2, and 1 grade 3.  For overall survival, risk was stratified based on the EQD2 cardiac dose. On univariate analysis, the 50% of cohort who received more than median mean heart dose (MHD) had poorer survival (p=0.00009, Figure 2) compared to the 50% who received below median MHD.



Conclusion

SABR patients can receive high doses to cardiac substructures. Further multivariate analysis is being performed to assess impact on survival.